Yazdian, Mahtab
Groeben, Harald
Ataseven, Beyhan
Schneider, Stephanie
Baert, Thais
Bommert, Mareike
Traut, Alexander
Elfers-Wassenhoven, Alexandra
Brüß, Ulrich
Schwameis, Richard
du Bois, Andreas
Wagner, Uwe
Harter, Philipp
Article History
Received: 5 August 2021
Accepted: 21 October 2021
First Online: 1 November 2021
Declarations
:
: The authors declare that there is no conflict of interest regarding the submitted work. Dr. Ataseven reports personal fees and non-financial support from Roche, personal fees from Amgen, personal fees from Astra Zeneca, personal fees and non-financial support from Tesaro/GSK, personal fees from Clovis, personal fees from Celgene, non-financial support from PharmaMar, outside the submitted work. Prof. du Bois reports personal fees and non-financial support from Roche, Astra Zeneca, Tesaro/GSK, Clovis, BIOCAD, non-financial support from Pfizer, Genmab/Seattle Genetics and MSD, outside the submitted work. Dr. Harter reports grants and personal fees from Astra Zeneca, grants and personal fees from Roche, personal fees from Sotio, grants and personal fees from Tesaro, personal fees from Stryker, personal fees from Zai Lab, personal fees from MSD, grants and personal fees from Public funding (ASCO, DKH, DFG), personal fees from Clovis, personal fees from Immunogen, grants and personal fees from GSK, grants from Boehringer Ingelheim, grants from Medac, grants from Genmab, outside the submitted work.
: All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. Informed consent was obtained from all individual participants included in the study.